Physicochemical stability and compatibility testing of levetiracetam in all-in-one parenteral nutrition admixtures in daily practice. by Aeberhard, Carla et al.
  	

Physicochemical stability and compatibility testing of levetiracetam in all-in-
one parenteral nutrition admixtures in daily practice
C. Aeberhard, C. Steuer, C. Saxer, A. Huber, Z. Stanga, S. Mu¨hlebach
PII: S0928-0987(16)30439-0
DOI: doi: 10.1016/j.ejps.2016.10.015
Reference: PHASCI 3761
To appear in:
Received date: 23 March 2016
Revised date: 10 October 2016
Accepted date: 11 October 2016
Please cite this article as: Aeberhard, C., Steuer, C., Saxer, C., Huber, A., Stanga,
Z., Mu¨hlebach, S., Physicochemical stability and compatibility testing of levetirac-
etam in all-in-one parenteral nutrition admixtures in daily practice, (2016), doi:
10.1016/j.ejps.2016.10.015
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could aﬀect the content, and all legal disclaimers that
apply to the journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
1 
 
Physicochemical stability and compatibility testing of 
Levetiracetam in all-in-one parenteral nutrition admixtures in daily 
practice 
 
 
Aeberhard C
1
, Steuer C
2, 
Saxer C
2
, Huber A
2
, Stanga Z
1
, Mühlebach S
3 
1
 Department of Endocrinology, Diabetes and Clinical Nutrition, Bern University 
Hospital, and University of Bern, Bern, Switzerland 
 
2 
Institute of Laboratory Medicine, Kantonsspital Aarau, Aarau, Switzerland 
3 
Division of Clinical Pharmacy and Epidemiology and Hospital Pharmacy, 
University of Basel, Basel, Switzerland 
 
 
 
 
 
 
 
Corresponding author 
Carla Aeberhard, Pharmacist, PhD Student 
Department of Endocrinology, Diabetes and Clinical Nutrition  
Bern University Hospital and University of Bern 
CH-3010 Bern 
Telephone: +41 31 632 42 46 
Fax:  +41 31 382 42 60 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
2 
 
E-mail: carla.aeberhard@insel.ch 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
3 
 
Abstract 
Background: Parenteral antiepileptic drugs are frequently used in critically ill 
patients for seizure control therapy or prevention. Many of these patients require 
additional parenteral nutrition (PN). Therefore, a parallel infusion of the frequently 
used antiepileptic drug levetiracetam (LEV) is interesting in terms of the restricted 
i.v. lines (e.g., neonates). The potential interactions of the complex PN admixture 
with the drug product and the appropriate admixing of a drug at effective dosages 
require physicochemical lab assessments to obtain specific and reliable 
pharmaceutical documentation for the intended admixing. 
Aim: To assess the of compatibility and stability of LEV, a neutral and hydrophilic 
drug, in commercial all-in-one (AiO) PN admixtures using simple validated tests to 
provide necessary data in a timely manner and to allow convenient, documented 
and safe treatment with PN as the drug vehicle. 
Methods: Different concentrations of LEV were injected into two different AiO PN 
admixtures with no further additives. Stability and compatibility tests for the drug 
and the PN admixtures were performed over seven days at +4 °C, +23 ± 1 °C and 
+37 °C without light protection. Stability and sample characteristics were 
observed by visual inspection and the validated light microscope method. 
Moreover, the pH level of the admixture was checked, as were the concentrations 
of LEV over time in the PN admixtures, using an established LC-MS/MS method. 
Results: The stability controls of LEV at different temperatures were within 
absolute ± 20% of the theoretical value in a concentration range of 98.91-
117.84% of the initial value. No changes in pH occurred (5.55 ± 0.04) and no 
microscopic out of specification data or visual changes were observed. The mean 
value of the largest lipid droplet in each visual field over seven days was 2.4 ± 
0.08 µm, comparable to that of the drug-free AiO admixture. Samples stored at 
+37 °C showed yellowish discolorations after 96 hours of storage. 
Conclusion: LEV showed compatibility and stability over seven days in the 
selected PN admixtures, and the described methods represented a valuable and 
timely approach to determine the stability and compatibility of the highly 
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hydrophilic, not dissociated LEV in AiO admixtures under conditions of use. 
Further studies with clinically relevant and representative examples of 
physicochemically different drug classes are needed.  
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Introduction 
Most hospitalized patients, especially critically ill patients requiring parenteral 
nutrition (PN) require additional intravenous (i.v.) medications. To prevent or to 
treat malnutrition, PN is necessary when the gastrointestinal feeding is inefficient, 
nonfunctional or not possible [1]. All-in-one (AiO) admixtures represent the 
standard for PN regimen and include an oil/water (o/w) emulsion containing 
approximately 50 individual and potentially reactive soluble components. 
Therefore, the potential physicochemical interactions among the components, the 
container and admixes, such as electrolytes, vitamins, trace elements to 
individualize the regimen, or even i.v. medications, are numerous. The 
formulation is too complex to be evaluated bibliographically. Accordingly, a lab 
analysis of the specific composition is needed. In principal, AiO PN admixtures do 
not represent suited vehicles to carry drugs, but in certain situations they may be 
convenient or otherwise beneficial (e.g., with limited separate i.v. access, as in 
neonates, or for compliance, in the home PN setting). Co-administering i.v. 
medications via Y-site together with PN or as added to AiO PN admixture, without 
documented compatibility/stability as a prerequisite for both drug and PN efficacy 
and safety is deemed unacceptable and represents an avoidable medication 
error. At a minimum, short-term physicochemical compatibility and stability data 
are required to guarantee quality and tolerance of such an individual 
pharmaceutical formulation. In current nutrition practice commercial multichamber 
AiO PN admixtures are used at least in the short term. Documented stability of 
such regimens are mandatory [2]. The most common instabilities from the o/w 
emulsion are creaming and coalescence; physicochemical reactions may be 
visible by colour or pH changes and by the formation of precipitates as a result of 
the degradation of components or reactions between nutrients and/or drugs. 
These reactions depend on various factors, including concentration, light 
exposure, temperature, catalyst actions, trace elements, or other components, 
such as electronically charged ions (e.g., dissociated drugs, electrolytes) [3]. This 
can also lead to major, even fatal complications, such as a venous catheter 
occlusion or blood vessel obstruction due to precipitates or enlarged lipid droplets 
(> 5μm) or deposits [4-6]. The United States Pharmacopeia requires that the 
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mean droplet size (MDS) of a parenteral lipid emulsion has to be < 5 µm and the 
volume-weighted percent of fat globules ≥ 5 µm (PFAT5) has to be < 0.05% 
(globule size distribution) [7]. To assess lipid emulsion deteriorations, simple 
analytical methods are mandatory to be used in a timely, reliable and cost-
effective manner in daily (pharmaceutical) hospital practice to ensure the stability 
or compatibility of ready-to-use individual AiO PN admixtures. 
There are many studies on the compatibility and stability of different medications 
that are admixed in PN [8-11]. However, most of these investigations are older 
(>10 years) and are done with analytical methods and techniques, not more state 
of the art. Furthermore, the composition of ready-to-use PN admixtures and the 
specific i.v. drug formulations have not been tested or have changed over time, 
and they may differ between manufacturers (e.g., generic drugs or individually 
manufactured, non- commercial hospital products). Therefore, it is very important 
to evaluate and document individual admixtures to achieve the best impact on 
medication practice and to avoid medication errors, especially when evaluating 
drugs that are frequently used in patients with PN. 
Antiepileptic drugs such as levetiracetam (LEV) i.v. are frequently used in critically 
ill patients for seizure control therapy or prevention and treatment of a status 
epilepticus (e.g., in patients after traumatic or surgical brain injury, cancer patients 
or neonates) [12]. Such patients mostly receive multiple lifesaving and potent 
parenteral medications and often require simultaneous administration with PN. 
LEV is a new-generation antiepileptic drug that is used with a larger therapeutic 
range with linear kinetics, in contrast to older antiepileptic drugs. There is a lack of 
published clinical data on the comparative efficacy of LEV given separately or 
admixed to a daily PN portion. In general, there is also limited literature about PN 
as a drug carrier for LEV or other antiepileptics. 
The aim of the present study was to evaluate the physicochemical compatibility 
and stability of LEV, which is an almost neutral and hydrophilic drug (see Fig. 1), 
admixed to commercialized PN AiO admixtures under practice conditions. In 
addition, suitable tests for timely assessment were proposed. Data are necessary 
to document this treatment framework because the possibility using of PN as a 
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drug carrier presents a new formulation with associated individual pharmaceutical 
quality responsibility. 
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Material and Methods 
The investigations were done from January to August 2015 in the laboratory 
medicine unit of the Cantonal Hospital (Aarau). The LEV injection solution of 500 
mg/5 mL (Levetiracetam Sandoz® concentrate for infusion; active pharmaceutical 
ingredient: Levetiracetam 100 mg/mL (Figure 1) [13], excipients: sodium acetate 
trihydrate, sodium chloride, water for injections for 1 mL) was obtained from 
Sandoz Pharmaceuticals AG, (Rotkreuz, Switzerland). Water, acetonitrile (ACN) 
and methanol (MeOH) were of LC-MS/MS grade and obtained from Sigma 
(Buchs, Switzerland). All other chemicals used were from Sigma (Buchs, 
Switzerland) and of analytical grade or otherwise indicated. Nutriflex® Lipid 
Special [NLS], 625 mL (lot:0333 F1) and Nutriflex® Omega Special [NOS], 625 ml 
(lot:0679 F1) (B Braun, Medical AG, Sempach, Switzerland), were used as PN 
admixtures (three-chamber-bags with separate lipid, glucose and amino acids 
compartments, Table 1). Three different LEV concentrations were used, 
representing a commonly adapted dosage range (20 mg/kg body weight) added 
to current PN regimens/volumes yielding LEV concentrations in the PN admixture 
of 0.4 mg/mL (≈2.35 mmol/L), 1.6 mg/mL (≈9.40 mmol/L) and 4.8 mg/mL (≈28.20 
mmol/L). Stability and compatibility tests were performed over seven days at 0, 
24, 48, 72 and 168 hours after admixing LEV injection solution into a PN sample. 
To prepare the test samples, the bag compartment seals were broken by 
mechanical pressing on the PN container. The bag was turned upside down five 
times for homogenization. Three samples (5 mL of PN) of each homogenized PN 
were transferred into 10 mL glass tubes using a 5 mL manual pipette. LEV 
injection solution was dosed by admixing 20 µL, 80 µL or 240 µL to the PN 
sample aliquots in the glass tubes, using manual pipettes. All pipettes in the 
range of 20-10’000 µL used had to pass the lab-internal testing within a specified 
accuracy of ± 1.0% and a coefficient of variation (CV) of ± 0.50%. The glass tube 
samples were covered with an airtight seal to provide an air- and fluid-tight seal. 
The test samples (PN with LEV) were stored in a refrigerator at +4 °C; at room 
temperature (23 ± 1 °C) in the laboratory; or at +37 °C (water bath). The samples 
were stored in transparent normal glass tubes without additional light protection. 
Samples stored and handled in the laboratory at room temperature or in the water 
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bath at elevated temperatures were exposed to daylight or artificial light (practical 
condition); samples stored in the refrigerator were protected from light by the 
closed door (“in the dark”). At each test time point, the samples in the tubes were 
visually inspected for discolorations, creaming, phase separation, or precipitates. 
Before taking an analytical sample, the tubes were turned upside down and back 
three times to guarantee a homogenous admixture. Three aliquots of each 
sample were measured by LC-MS/MS and then statistically calculated for drug 
concentration (mean ± SD for each sample). For the identification and 
quantification of LEV, a Thermo Fischer Ultimate 3000 UHPLC system (Thermo 
Fisher, San Jose, CA, USA) coupled to an ABSciex 4500 quadrupole mass 
spectrometer (ABSciex, Darmstadt, Germany) was used with a commercial kit 
(AED MassTox panel, Chromsystems, München, Germany). Mobile phases I and 
II were from Chromsystems, München, Germany [14]. The MS was run in the 
multiple reactions monitoring (MRM) mode using two transitions for each analyte. 
The Turbo V ion source run in positive ESI mode. Preparation and clean-up of the 
samples was performed according to the manufacturer`s protocol for serum 
samples [15]. Matrix effects and extraction recoveries were determined for serum 
and PN, as proposed by Matuszewski et. al.[16]. Three aliquots of all three 
concentrations were used. Thereby, the stock solution was diluted 1+1 (1:2) and 
also 1+99 (1:100). Sample aliquots of 50 µL were put into Eppendorf tubes, mixed 
with 25 µL of extraction buffer, vortexed for 10 seconds and then incubated for 
two minutes at room temperature. The internal standard mix (250 µL, containing 
precipitation reagent) was added, vortexed for 30 seconds and then centrifuged 
for five minutes at 13’000 rpm. Ten µL of the supernatant was mixed with 1090 µL 
of dilution buffer. The injection volume was 10 µL, and the LC flow rate was 0.6 
mL/min. The injection was done by a thermo-controlled autosampler at room 
temperature (Thermo Scientific, Dionex UltiMate 3000), and the quantification 
was done according to a calibration curve, normalized to the corresponding 
internal standard. 
Light microscope investigations for lipid droplet assessment and pH 
measurements (Metrohm 744 pH Meter) were performed for NOS and NLS as 
blanks and with concentrations of 1.6 mg/mL LEV (9.40 mmol/L) at +4 °C, +23 ± 1 
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°C and +37 °C. Before each pH measurement, a two-point calibration of the pH 
meter was done, each with a buffer solution of pH 9.00 and pH 4.00, respectively 
(Metrohm calibration buffer). The pH 7.00 solution was used afterwards as a 
control. Between the calibration steps, the electrode was rinsed with distilled 
water and wiped dry.  
The physical stability of lipid emulsion was assessed by lipid droplet measuring in 
a light microscope (BX51 Olympus) with an upper droplet size of ≥ 1 μm. Each 
microscopic sample (10 µL by a manual pipette) was analysed with 100-fold 
magnification and oil immersion [17]. Five individual visual fields were inspected 
per microscopic sample (15 total visual fields/aliquot): four in the corner and one 
in the middle of the preparation. The size of the lipid droplets in the visual field 
was determined using an ocular micrometre (0.01 mm). The diameter of the 
largest lipid droplet (LLD) and the number of lipid droplets > 5 µm were measured 
and counted in each of the 15 visual fields tested per aliquot. The stability-
indicating data were measured and calculated according to Schmutz (thesis). The 
specifications [17] of microscopic screening are shown in Table 2. 
The statistical assessment was performed with IBM SPSS Statistics for Windows, 
Version 19.0 (IBM Corp. Released 2010, Armonk, NY, USA) and Prism 6 for Mac 
OS X, Version 6.0 (GraphPad Software). The results are reported as the means 
with standard deviations (mean ± SD) or as numbers and percentages (n, %). In 
addition, 95% confidence intervals, R
2
, two-tailed P test, and one/two-way 
ANOVA were calculated. A p-value <0.05 was considered statistically significant.  
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Results 
Microscopic analysis 
The microscopic results of NOS and NLS with LEV (1.6 mg/mL) are shown in 
Table 3. The mean of the largest lipid droplet in µm out of 15 visual fields (n) 
(MLLDmax) of 4.5 µm as the upper limit value for the emulsion stability was never 
reached by any sample over the seven-day analysis period. The mean value of 
the MLLDmax for NOS (at all temperatures and throughout the storage duration) 
was 2.3 ± 0.60 µm (n=180) and for NLS was 2.6 ± 0.63 µm (n=180). There was a 
trend for the droplet size to increase over time, as shown in Figure 2. The upper 
limit specification (specifications shown in Table 2) of a LLD in 15 visual fields of ≤ 
8 µm was always reached. The LLD measured had a diameter of 8 µm (n=1). The 
highest SD was 1.99 µm and was thus always smaller than the 2.0 µm 
specification. Similarly, the number of lipid droplets > 5 µm was three was thus 
always smaller than the specification of nine. 
The MLLDmax of NOS and for NLS as blank samples at all temperatures and over 
the entire storage duration was 2.6 ± 0.77 and 2.7 ± 0.69, respectively, showing 
comparable emulsion characteristics, and the data were within the specifications. 
There was no statistically significant difference between the blank samples and 
the samples with added LEV (p=0.1602, two-way ANOVA). These specifications 
were not dependent on temperature (4-37 °C), and no difference of the different 
lipid compositions of NOS and NLS could be detected. The microscopic 
assessment of lipid droplets per sample (15 visual fields) took approximately 20 
minutes. 
 
pH determination 
The pH of the different PN admixtures samples (with and without 1.6 mg/mL LEV) 
at three different temperatures decreased negligibly over time in NOS and NLS 
but ranged in all samples from 5.47 to 5.63 (mean ± SD: 5.55 ± 0.04, n=48), with 
no detectable changes during the test period. There was no difference regarding 
the different lipid compositions, and no temperature dependency was shown. 
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Visual inspection 
Over seven days, no visual changes were observed in the test samples stored at 
+4 °C or at room temperature. There was no creaming or discoloration, except for 
the samples stored at +37 °C which showed yellowish discolorations after 96 
hours. However, neither precipitates nor flocculation were visible. A visual 
inspection was done for the assessment of large particle formation in the critical 
size 1-5 μm. 
 
LC-MS/MS analysis 
Extraction recoveries and matrix effects for PN and serum were tested for two 
LEV concentrations. Serum analysis is described because this lab method was 
validated for therapeutic drug monitoring (TDM) in serum samples and has 
therefore to be checked when alternative samples were measured. Since the PN 
admixtures samples used produced no matrix effects, the analysis could be 
directly used for the stability measurements in NOS and NLS. The extraction 
recovery for PN samples for the lower concentration (0.4 mg/mL) was 98.7% 
(n=5, SD=5.53) resp. 86.0% (n=5, SD=5.77) for the higher concentration (4.8 
mg/mL). The recovery rate for serum samples was 99% (n=5, SD=5.01) resp. 
92.7% (n=5, SD=6.35). No matrix effects were observed: the matrix effect for PN 
samples ranged from 90.9-101.3% and from 97.2 -105.1% for serum samples. 
No differences between NOS and NLS (as blanks) were observed for selected 
incubation/storage temperatures (one-way ANOVA: F=1.357, p=0.2655, 
R
2
=0.0677). The three different LEV concentrations in NLS at +37 °C measured 
over 7 days were 0.43 ± 0.02 mg/mL, 1.76 ± 0.07 mg/mL, and 5.07 ± 0.15 mg/mL 
respectively. At room temperature, the following LEV concentration over time 
resulted: 0.43 ± 0.01 mg/mL, 1.83 ± 0.11 mg/mL resp. 5.11 ± 0.23 mg/mL . No 
storage temperature dependency was detectable, when comparing room 
temperature vs. +37 °C (two-tailed t-Test, p=0.3078). Also no significant 
difference was shown regarding concentration dependency (one-way ANOVA: 
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F=3.084, p=0.0643, R2=0.2044). The measured LEV concentrations in NOS at 
+37 °C were 0.43 ± 0.02 mg/mL, 1.72 ± 0.07 mg/mL resp. 4.96 ± 0.21 mg/mL. 
The measurements in NOS at room temperature resulted in 0.41 ± 0.01 mg/mL, 
1.8±0.05 mg/mL resp. 5.25 ± 0.28 mg/mL. There was no significant change of the 
LEV concentration detectable over seven days when comparing the data at RT 
and +37 °C (two-tailed t-Test, p=0.2029). Additionally, there was no significant 
concentration dependency detectable (one-way ANOVA: F=3.037, p=0.0646, R
2 
=0.1836). All results were in the range of ± 20%. The imprecision was within ± 
20%. As the LEV measurements were done in highly complex o/w PN samples 
comparable to bioanalytical samples, the 20% range for deviation was applied. 
Although the best fit line showed negative trend over the storage time (y=-
0.0259x+108.7, R
2
=0.0847), no significant decline of the concentration resulted 
from one-way ANOVA: F=2.124, p=0.1076, R
2
=0.2537. The individual dot in the 
stability over time plot indicates the mean of the three measurements expressed 
in % of initial concentration of LEV in NOS at room temperature and at +37 °C. 
(Figure 3).  
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Discussion 
Although this stability assessment procedure is aimed for a more general 
approach how to evaluate on a short term base drug-PN stability and compatibility 
request in a hospital setting with easy to realise lab investigations available in 
teaching hospitals and pharmacies, it is important to validate the approach by 
appropriate investigations on representative and relevant drug products. In this 
study we selected LEV (Figure 1), a highly water soluble (> 100g/100 mL of 
water) low molecular pyrrolidine anticonvulsant representative. This amid drug 
has a pKa of -2 and is almost not protein-bound. Therefore, it represents a very 
hydrophilic (logP of -0.6), neutral not dissociated drug compound used 
therapeutically in molar doses (1000 mg ~ 6 moles) [13,18]. A review showed that 
anticonvulsants are often used together with PN in traumatic brain injuries and in 
cancer patients [19]. Stability and compatibility data with PN are scare, although it 
is a relevant and frequently used drug for critically ill patients or neonates. 
Medications often describe Y-site administration and do not address the chemical 
stability, which is important for efficacy and safety. 
LEV in a dose range of 0.4-4.8 mg/mL (2.35-28.20 mmol/L) is a highly dosed i.v. 
drug and may thus have compatibility concerns. There was no significant 
decrease over seven days in NOS and NLS at three different temperatures. The 
assessment of the chemical stability of LEV was done using a validated stability-
indicating LC-MS/MS quantification method that is also used for TDM. LC-MS/MS 
investigations involve highly sensitive, state-of-the-art identification and 
quantification methods with drug-specific detection available in most tertiary 
hospital medical labs (see chromatogram of LEV in Figure 4). The advantages of 
the LC-MS/MS method vs. HPLC-UV or –FLD (with fluorescence detector) - are 
the most simple and fast sample preparation, substantially less interference e.g. 
by co-medications, a shorter run-time and consequently a higher sample 
throughput and selectivity - clearly predominate a potential lower precision. But 
using a (deuterated) internal standards, a complete and good precision through 
all clean-up steps of the analysis can be achieved. Therefore, and as the drug 
stability / compatibility evaluation in PN can rely on an existing validated and 
verified LC-MS/MS method used within the TDM-panel in the institutional routine 
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operation of a hospital, their use is within the scope of the investigation for 
relatively easy access methods to get stability indicating data. 
The analysis of the matrix effect and the extraction recovery showed the 
applicability for PN samples and using the serum sample cleanup. The three 
different LEV concentrations chosen correspond to the usual LEV dosing from 2x 
250 mg to 2x 1500 mg applied in usual PN volumes (administered daily). The 
lower level (250 mg) and upper level (3000 mg) concentrations admixed to 625 
mL PN yielded a concentration of LEV of 0.4 mg/mL, 1.6 mg/mL and 4.8 mg/mL. 
Admixed into 1250 mL PN (for adults), this would result in a concentration of 0.2 
mg/mL, 0.8 mg/mL and 2.4 mg/mL. In addition, it was shown that LEV could be 
dosed in half of the volume due to its high solubility. 
All of the measured concentrations of LEV in NOS and NLS were in the range of 
± 20% of the theoretical value. The different temperature (storage) conditions 
used for two different high drug concentrations showed no influence on the 
stability of LEV. The variability (higher concentration after storage) can be 
explained by pipetting errors during the sample preparation or by the dilution, 
which yields an incorrect 100% target value. The volume ratio for the PN sample 
and the drug admixture was ≥ 1:20 and was therefore sensitive to small pipetting 
errors. The accuracy of the pipettes is shown above. 
The AiO PN admixtures that were chosen are representative treatments for 
patients; they require PN administration through a centrally placed i.v. catheter 
(osmolality >> 800 mosmol). The two products differ in the fatty acid (FA) 
composition of the fat emulsion (Table 1). These PN products are prefilled, stable, 
three-chamber formulations, that can readily be made and used in most patients. 
Commercially available lipid emulsions have a mean particle size of 
approximately 0.25-0.5 µm in diameter, which corresponds to chylomicrons. The 
growth of the lipid droplets into large fat globules could also block small blood 
vessel (> 5 µm), e.g., in the lung, and are dangerous formulations that should not 
be used in patients [5,20]. The light microscope method according to Schmutz et 
al. is highly sensitive and practicable, with a simple equipment and a conventional 
method validated by Photon Correlation Spectroscopy (PCS) and the Coulter
R
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method. Using a microscope with a 100-fold magnification allows the detection of 
particles approximately 1 µm in size or enlarged emulsion particles up to 20 µm in 
size. Furthermore, other non-lipid globules (such as particulate matters or 
precipitations) can also be detected using this method. The method provides an 
easy, sensitive, cost-efficient, time-sparing, and convenient way to test the 
physical stability of a lipid emulsion in the critical droplet size to indicate 
destabilisation (large fat droplet assessment ≥ 1-2 μm), and it is suitable for drug 
incompatibility testing in AiO PN admixtures [17]. 
LEV did not affect the lipid droplet sizing in microscopy assay over at least 24 
hours and only showed only a slightly increasing MLLDmax over a week at 
elevated temperatures (Fig. 2,3). Because the chemical analysis with LC-MS/MS 
showed that LEV possessed good stability in all three concentrations, only the 
concentration of 1.6 mg/mL was analysed by microscope. No influence of the FA 
composition on lipid stability could be detected. A single in vitro study showed 
LEV stability over 91 days in Ora-Sweet (a syrup vehicle used to simplify the 
process of flavouring and sweetening) and Ora-Plus (suspension adjuvant) at two 
different temperatures [21]. Our results showed that MLLDmax in each visual field 
over seven days at three different temperatures was 2.3 ± 0.60 µm for NOS resp. 
2.6 ± 0.63 µm for NLS and did not differ from the PN without the drug. No trend 
for an increase in the mean droplet size was seen when 9.40 mmol/L LEV was 
added. All other parameters were according to the specs. This supports the 
position of using physicochemical drug characteristics as a first evaluation of the 
incompatibility risk or the critical emulsion deterioration potential. Nevertheless, a 
lab analysis for such complex pharmaceutical formulation is necessary to 
document the pharmaceutical appropriateness of such medication and needs 
pharmaceutical expertise in the NST. 
The aim of the present study was to use simple and time-saving evaluation tests 
to assess physicochemical stability and compatibility of LEV admixed to two 
common commercial AiO PN admixtures. The investigation was able to 
demonstrate easy-to-administer tests and document the compatibility and stability 
of the drug in these PN products. Pharmacists could use such tests in daily 
practice upon the request of such data as a prerequisite for safe and efficacious 
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treatment advice and to prevent incorrect handling and medication errors [22]. 
Another factor indicating the stability of PN AiO admixtures is the pH. The pH 
decreases over time in PN admixtures because of the hydrolysis of fat 
triglycerides. Additional chemical reactions yielding base or acidic products also 
affect the pH. For the lipid stability and lecithin emulsifier, a pH range of 5-8 is 
necessary. The negatively charged surface (phosphate moiety) prevents the 
coalescence of the lipid globules [2]. A pH below 5.0 favours lipid instabilities [23]. 
In our study, there was only a slightly decreasing pH over time (most affected the 
samples at +37 °C) because of destabilisation, degradation, and polymerisation 
but not a LEV-specific reaction. 
All of the presented data are based on tests that were done in 10 mL glass tubes, 
whereas in reality, the two solutions would be mixed in either a Y-line, or in the 
PN bag if the drug was added there. Previous studies have evaluated the 
compatibility between PN admixtures and medications in a static manner [24, 25] 
or by simulating Y-site administration [11]. This study with the aim to get a 
response on drug stability and compatibility quickly in a given design simulates 
“worst-case” conditions with a defined contact time between the PN admixtures 
and a given drug concentration (LEV) but also to check the stability for drug and 
PN at daylight and storage at room temperature and at +37 °C but only in glass 
containers. To transfer the data to other containers or medical device materials, 
further studies have to be done, especially if reports e.g. drug adsorption or 
absorption exist like for lipophilic drugs and some plastics like PVC. This is not 
the case for LEV. 
A limitation of the study is the fact that these results are related to PN regimen 
without vitamins or trace elements and the need for (home) PN, but there is a low 
risk from the LEV characteristics that additional interactions with these 
micronutrients would occur (red-ox reactions). An additional limitation is that only 
one specialty of LEV and only two different PN were checked. However, again, 
there is limited evidence of major differences among originator and generic i.v. 
formulations, although generic drugs may potentially not have identical 
ingredients or pH differences. Other PN regimes might differ in composition, but 
with a hydrosoluble, almost neutral drug such as LEV, there is a low risk for major 
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incompatibility. In either case another series with different PN regimens could be 
done in a relatively short time. Additionally, the neonatal situation was not 
specifically assessed. Neonates often have very limited line access, individual PN 
regimes and lower medication dosage, and LEV is a candidate for such an 
admixture. Because we performed in vitro pharmaceutical analysis and no in vivo 
clinical assessment, it would be beneficial to assess this stable pharmaceutical 
formulation in vivo. The absence of data on in vivo effects is a limit of these 
stability assessments and would be valuable for common drugs. The aim of this 
study was to demonstrate how incompatibilities and, therefore, unsafe and 
ineffective admixtures can simply be tested via a pharmaceutical approach.  
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Conclusion 
We investigated the compatibility and stability of LEV in two common, 
commercially available PN AiO admixtures in adults at conditions of usual 
handling in a hospital. LEV demonstrated compatibility and stability in NOS and 
NLS in a concentration of 1.6 mg/mL (9.40 mmol/L) at three different 
temperatures. In addition, these results illustrated a valuable approach for 
determining the pharmaceutical stability and compatibility of drugs with PN in 
practice. This timely and cost-effective pharmaceutical approach of documenting 
the quality of complex therapeutic regimens increases the convenience and 
avoids medical errors in the clinical setting. It is crucial to combine methods to 
obtain a robust analysis of the chemical and physical stability of such admixtures. 
The demonstrated example of LEV admixed to AiO PN is important in patient 
care, is representative of drugs that are hydrophilic-neutral or that have weak 
acidity, and documents pharmacists’ support for critical medication treatments in 
hospital practice. This procedure can be easily applied in daily clinical practice to 
fulfill the demands of determining stability and compatibility of different drugs in 
PN mixtures, when co-administration with PN and medications cannot be 
avoided. In future studies, we will analyse drugs with varying physicochemical 
profiles and clinical importance to further validate the procedure.  
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Table 1: Product information of the composition of tested TPN (NOS and NLS), in 625 
ml bags 
ingredient 
unit NuTRIflex® Omega 
special 
NuTRIflex® Lipid 
special 
Volume glucose solution ml 250 250 
Glucose monohydrate g 99.0 99.0 
Sodium dihydrogen 
phosphate dihydrate 
g 1.56 1.56 
Zinc acetate dihydrate mg 4.39 4.39 
Volume fat emulsion  mL 125 125 
Soya-bean oil g 10.0 12.5 
Medium-chain triglycerides g 12.5 12.5 
Omega-3 fatty acids g 2.5 - 
Monounsaturated fatty 
acids 
% 11.4 13 
Polyunsaturated fatty 
acids 
% 34.0 30.7 
Ratio Ω-3:Ω-6  1:2.7 1:7 
Essential fatty acids % 31.7 30.7 
Volume amino acid 
solution* 
mL 250 250 
Amino acid content g 35.9 35 
Nitrogen content g 5 5 
Carbohydrate content g 90 90 
Lipid content g 25 25 
Non-protein energy kJ (kcal) 2505 (600) 2505 (600)  
Total energy kJ (kcal) 3090 (740) 3088 (738) 
Osmolality (mOsm/kg) 2170 2090 
pH-value  5.0-6.0 5.0-6.0 
* not detailed  
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Table 2: Specifications of microscopic i.v. fat emulsion stability screening in 15 visual 
fields [17]  
 
 
 
  
Microscopic parameter Abbreviation Unit Specification 
Largest lipid droplet in 15 fields LLD 1-15 [µm] ≤ 8 
Mean LLD MLLDmax [µm] < 4.5 
Standard Deviation SDLLD [µm] ≤ 2.0 
Number of lipid droplets >5µm LD > 5 µm [n] ≤ 9 
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Table 3: Emulsion stability assessed by microscopic analysis of LEV (1.6 mg/mL) 
admixed to NOS and NLS and stored at three different temperatures 
PN  NOS NLS 
temperature  23±1 °C +37 °C  +4 °C 23±1 °C +37 °C  +4 °C 
parameter MLLDmax  [µm]  
s
to
ra
g
e
 
d
u
ra
ti
o
n
 
0 1.5 1.2 1.8 1.7 2.3 1.5 
24 2.3 2.1 1.9 2.5 3.3 2.2 
96 3.3 2.4 2.9 2.4 3.3 3.1 
168 2.7 2.7 2.6 3.3 2.5 3.1 
parameter LLD 1-15 [µm] 
s
to
ra
g
e
 
d
u
ra
ti
o
n
 
0 3 3 4 5 4 3 
24 6 4 5 5 6 4 
96 6 4 6 5 5 6 
168 6 5 8 7 5 6 
parameter SDLLD [µm] 
s
to
ra
g
e
 
d
u
ra
ti
o
n
 
0 0.74 0.77 0.86 1.23 1.22 1.06 
24 1.68 1.06 1.03 0.99 1.53 1.08 
96 1.45 1.12 1.41 1.18 1.22 1.30 
168 1.45 0.90 1.99 1.53 1.46 1.33 
parameter LD > 5 µm [n] 
s
to
ra
g
e
 
d
u
ra
ti
o
n
 
0 0 0 0 0 0 2 
24 1 0 0 0 3 0 
96 2 0 1 0 0 1 
168 3 0 0 2 0 1 
 
LEV: Levetiracetam; NOS: Nutriflex® Omega Special; NLS: Nutriflex® Lipid Special; RT: room 
temperature 
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Figure 1: Formula for Levetiracetam (C8H14N2O2; MG=170.2 g/mol; logP -0.6; pH 7.0) 
[13] 
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Figure 2: Mean values of the largest lipid droplet of NOS and NLS with LEV over time at 
three different temperatures 
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Figure 3: Stability of LEV in NOS over time determined by LC-MS/MS in mg/mL (room 
temperature and at +37 °C) 
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Figure 4: Extracted ion chromatogram (XIC) of Levetiracetam (1; yellow and cyan) and 
internal standard (2; grey). 
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